How we treat cytomegalovirus in hematopoietic cell transplant recipients

Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor

1995 • 1,828 citations

Definitions of Cytomegalovirus Infection and Disease in Transplant Recipients

2002 • 1,213 citations

Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

2002 • 710 citations

Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age

2001 • 687 citations

Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease

1991 • 686 citations

Ganciclovir Prophylaxis To Prevent Cytomegalovirus Disease after Allogeneic Marrow Transplant

1993 • 679 citations

Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study

1996 • 677 citations

A Randomized, Controlled Trial of Prophylactic Ganciclovir for Cytomegalovirus Pulmonary Infection in Recipients of Allogeneic Bone Marrow Transplants

1991 • 640 citations

A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant [see comments]

1995 • 629 citations

Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity

2002 • 602 citations

Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia

2007 • 569 citations

Treatment of Cytomegalovirus Pneumonia with Ganciclovir and Intravenous Cytomegalovirus Immunoglobulin in Patients with Bone Marrow Transplants

1988 • 550 citations

Cytomegalovirus Reactivation in Critically Ill Immunocompetent Patients

2008 • 537 citations

Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation

2000 • 528 citations

Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow Transplantation

1986 • 528 citations

Cytomegalovirus Pneumonia after Bone Marrow Transplantation Successfully Treated with the Combination of Ganciclovir and High-Dose Intravenous Immune Globulin

1988 • 499 citations

The Antiviral Activities of Artemisinin and Artesunate

2008 • 474 citations

Acyclovir for Prevention of Cytomegalovirus Infection and Disease after Allogeneic Marrow Transplantation

1988 • 456 citations

Quantitation of Cytomegalovirus: Methodologic Aspects and Clinical Applications

1998 • 445 citations

Ganciclovir Prophylaxis of Cytomegalovirus Infection and Disease in Allogeneic Bone Marrow Transplant Recipients: Results of a Placebo-Controlled, Double-Blind Trial

1993 • 433 citations

Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies

2003 • 431 citations

High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)–Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV Infection

2002 • 406 citations

Immunomodulatory and Antimicrobial Efficacy of Intravenous Immunoglobulin in Bone Marrow Transplantation

1990 • 398 citations

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

2003 • 370 citations

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation

2000 • 344 citations

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

2002 • 323 citations

Intravenous Immune Globulin for Prevention of Cytomegalovirus Infection and Interstitial Pneumonia After Bone Marrow Transplantation

1987 • 302 citations

Reactivation of Cytomegalovirus Infection in Critically Ill Immunocompetent Patients—Reply

2008 • 290 citations

Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation

1994 • 284 citations

Cytomegalovirus infection after bone marrow transplantation: an association with acute graft-v-host disease

1986 • 275 citations

Optimization of Quantitative Detection of Cytomegalovirus DNA in Plasma by Real-Time PCR

2004 • 259 citations

Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis

2003 • 248 citations

Corticosteroids can reverse severe imatinib-induced hepatotoxicity.

2006 • 246 citations

Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation

2003 • 242 citations

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

2008 • 240 citations

Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products

2003 • 232 citations

Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection

2000 • 229 citations

Neutropenia in Allogeneic Marrow Transplant Recipients Receiving Ganciclovir for Prevention of Cytomegalovirus Disease: Risk Factors and Outcome

1997 • 220 citations

Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes

2001 • 213 citations

Treatment of Interstitial Pneumonitis Due to Cytomegalovirus with Ganciclovir and Intravenous Immune Globulin: Experience of European Bone Marrow Transplant Group

1992 • 199 citations

Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy

2000 • 198 citations

Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir

2008 • 196 citations

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

2002 • 184 citations

Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease

1997 • 172 citations

Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation

2005 • 170 citations

Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients.

1988 • 146 citations

Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers

2001 • 141 citations

Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis

2007 • 138 citations

Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies

2007 • 135 citations

Definition of a subset of human peripheral blood mononuclear cells that are permissive to human cytomegalovirus infection

1993 • 132 citations

GANCICLOVIR/IMMUNOGLOBULIN COMBINATION THERAPY FOR THE TREATMENT OF HUMAN CYTOMEGALOVIRUS-ASSOCIATED INTERSTITIAL PNEUMONIA IN BONE MARROW ALLOGRAFT RECIPIENTS

1988 • 131 citations

Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro

2005 • 130 citations

Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet

2006 • 129 citations

Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders

2006 • 125 citations

Virological, Clinical, and Ophthalmologic Features of Cytomegalovirus Retinitis after Hematopoietic Stem Cell Transplantation

2001 • 121 citations

Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease after Allogeneic Bone Marrow Transplantation

2003 • 120 citations

Human cytomegalovirus infection alters the substrate specificities and rapamycin sensitivities of raptor- and rictor-containing complexes

2006 • 116 citations

Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation

2005 • 113 citations

Should Immunoglobulin Therapy Be Used in Allogeneic Stem-Cell Transplantation?

2003 • 112 citations

Cytomegalovirus (CMV)-Specific Intravenous Immunoglobulin for the Prevention of Primary CMV Infection and Disease after Marrow Transplant

1991 • 111 citations

Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.

1993 • 110 citations

Cytomegalovirus seropositivity adversely influences outcome after T‐depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft‐versus‐host disease prophylaxis

2001 • 108 citations

Late Cytomegalovirus Disease in Marrow Transplantation Is Predicted by Virus Load in Plasma

1997 • 104 citations

Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection

2004 • 102 citations

Cytomegalovirus (CMV) DNA Load in Plasma for the Diagnosis of CMV Disease before Engraftment in Hematopoietic Stem‐Cell Transplant Recipients

2001 • 102 citations

Clinical features and outcomes of cytomegalovirus retinitis after transplantation

2007 • 102 citations

Proceedings of a Consensus Conference: Prevention of Post-Transfusion CMV in the Era of Universal Leukoreduction1

2001 • 97 citations

Phase I-II Trial of Foscarnet for Prevention of Cytomegalovirus Infection in Autologous and Allogeneic Marrow Transplant Recipients

1992 • 97 citations

CYTOMEGALOVIRUS-INDUCED CD13-SPECIFIC AUTOIMMUNITY-A POSSIBLE CAUSE OF CHRONIC GRAFT-VERSUS-HOST DISEASE1

1996 • 96 citations

Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy

2007 • 94 citations

Maribavir Antagonizes the Antiviral Action of Ganciclovir on Human Cytomegalovirus

2006 • 88 citations

CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy

2000 • 88 citations

Use of intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic bone marrow transplant patients: a report from the European Group for Blood and Marrow Transplantation (EBMT)

1998 • 79 citations

Cytomegalovirus viraemia and specific T‐helper cell responses as predictors of disease after allogeneic marrow transplantation

1993 • 79 citations

Prophylactic use of ganciclovir in allogeneic bone marrow transplantation: absence of clinical cytomegalovirus infection

1991 • 79 citations

Rapid diagnosis of cytomegalovirus pneumonia in marrow transplant recipients by bronchoalveolar lavage using the polymerase chain reaction, virus culture, and the direct immunostaining of alveolar cells

1993 • 78 citations

Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT

2007 • 76 citations

Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation

2007 • 74 citations

Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial

2003 • 71 citations

Evidence‐based recommendations for the use of WBC‐reduced cellular blood components

2001 • 71 citations

Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation

2001 • 67 citations

RECOGNITION AND RAPID DIAGNOSIS OF UPPER GASTROINTESTINAL CYTOMEGALOVIRUS INFECTION IN MARROW TRANSPLANT RECIPIENTS

1994 • 66 citations

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host Disease of the Gastrointestinal Tract

2006 • 66 citations

Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants

2004 • 64 citations

Leukocyte Depleted, Unscreened Blood Products Give a Low Risk for CMV Infection and Disease in CMV Seronegative Allogeneic Stem Cell Transplant Recipients with Seronegative Stem Cell Donors

2002 • 63 citations

Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT

2000 • 61 citations

Dendritic Cell Vaccination in Allogeneic Stem Cell Recipients: Induction of Human Cytomegalovirus (HCMV)–Specific Cytotoxic T Lymphocyte Responses Even in Patients Receiving a Transplant from an HCMV‐Seronegative Donor

2007 • 58 citations

Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis.

1994 • 57 citations

CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections.

1994 • 56 citations

No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients

1997 • 55 citations

Influence of Cytomegalovirus Seropositivity on Outcome after T Cell–Depleted Bone Marrow Transplantation: Contrasting Results between Recipients of Grafts from Related and Unrelated Donors

2002 • 52 citations

Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?

2004 • 52 citations

Umbilical cord blood transplantation and cytomegalovirus: posttransplantation infection and donor screening

2006 • 52 citations

Contemporary management of cytomegalovirus infection in transplant recipients: guidelines from an IHMF workshop, 2007.

2008 • 46 citations

Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation

2005 • 45 citations

Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study

2000 • 44 citations

Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation.

2001 • 42 citations

Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.

1994 • 40 citations

A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).

1998 • 39 citations

Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus

2004 • 36 citations

Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients. Australasian Bone Marrow Transplant Study Group.

1995 • 36 citations

The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs

2004 • 35 citations

Cytomegalovirus Reactivation in Pediatric Hemopoietic Progenitors Transplant

2005 • 29 citations

Prophylactic use of ganciclovir for allogeneic bone marrow transplant recipients.

1993 • 28 citations

Systemic lupus erythematosus-related autoantibody production in mice is determined by bone marrow-derived cells.

1993 • 27 citations

Susceptibility of human cytomegalovirus to two-drug combinations in vitro.

1996 • 24 citations

Impact of cytomegalovirus serostatus on outcome of unrelated cord blood transplantation for adults: a single‐institute experience in Japan

2007 • 23 citations

75: Prevention of Late CMV Disease After HCT: A Randomized Double-Blind Multicenter Trial of Valganciclovir (VGCV) Prophylaxis Versus PCR-guided GCV/VGCV Preemptive Therapy

2008 • 8 citations